Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL
Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.
You may also be interested in...
One day after reporting that its umbralisib/ublituximab combo met a PFS endpoint in CLL, TG raises $60m as it prepares for a year-end filing of the combo. Umbralisib monotherapy is under FDA review already.
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.